London
· Delayed Price · Currency is GBP · Price in EUR Orion Oyj Company Description
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally.
The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies.
It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products.
Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
| Country | Finland |
| Founded | 1917 |
| Industry | Pharmaceutical Preparations |
| Employees | 3,632 |
| CEO | Liisa Hurme |
Contact Details
Address: Orionintie 1A Espoo, 02200 Finland | |
| Phone | 358 10 4261 |
| Website | orion.fi |
Stock Details
| Ticker Symbol | 0M2N |
| Exchange | London Stock Exchange |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timo Lappalainen | Chief Executive Officer, President and Chairman of the Executive Management Board |
| Jari Karlson M.Sc., M.Sc. (Econ.) | Chief Financial Officer, Senior Vice President of Animal Health and Member of the Executive Management Board |
| Olli Huotari Ll.M. | Senior Vice President of Corporate Functions, General Counsel, Secretary and Member of Executive Management Board |
| Satu Ahomäki M.Sc. (Econ.) | Senior Vice President of Commercial Operations and Member of the Exe. Mgmt. Board |
| Dr. Liisa Hurme | Senior Vice President of Global Operations and Member of the Executive Management Board |
| Virve Laitinen M.Sc. (Tech.), MBA | Senior Vice President of Specialty Products and Member of Executive Management Board |
| Prof. Outi Vaarala M.D., Ph.D. | Senior Vice President for Research & Development and Member of Executive Management Board |
| Tuukka Hirvonen M.Sc.(Soc.) | Investor Relations and Financial Communications Officer |
| Terhi Ormio | Vice President of Communications |
| Prof. Heikki Joensuu M.D., Ph.D. | R&D Global Head of Therapy Area Oncology |